【摘要】 由新型冠状病毒(SARS-Cov-2)所致的新型冠状病毒肺炎(COVID-19)疫情严峻,目前尚缺乏特效抗病毒药物。中医药在新冠肺炎治疗中起到举足轻重的作用,黄芩是国家卫生健康委员会新型冠状病毒肺炎诊疗方案推荐的清肺排毒汤以及武汉协和2号方和3号方的重要组成部分。黄芩素是黄芩的主要药效物质基础,具有抗病毒、抗菌、抗过敏、免疫调节等多种药理作用,具有广阔的开发前景。本文就黄芩素的临床前和临床研究、潜在的药物相互作用等方面的进展进行了系统综述,为黄芩素的进一步开发和临床应用奠定基础。更多还原

【Abstract】 The 2019 new coronavirus pneumonia(COVID-19) caused by the new coronavirus(SARS-Cov-2) infection has become a global pandemic,and currently there is a lack of specific antiviral drugs.Traditional Chinese medicine plays a critical role in the treatment of COVID-19.Scutellaria baicalensis is an important component of the Qingfei Paidu decoction recommended in the Chinese National Health Commission ’s Treatment Regimen and Wuhan Xiehe No.2 and No.3 prescriptions as well.Baicalein is the main ingredient in Scutellaria baicalensis,and has various pharmacological effects such as antiviral,antibacterial,antiallergic,and immunomodulatory activities,showing a broad prospect in new drug development.This article systemically reviewed the recent progress in the preclinical and clinical studies,potential drug interactions,and other aspects of baicalein,which will help further development and clinical application of the drug.更多还原